Teva Pharma (TEVA) Tops Q3 EPS by 7c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Reports Third Quarter 2015 Results
October 29, 2015 7:00 AM EDTRevenues of $4.8 billion, down 5% compared to the third quarter of 2014. Excluding the impact of foreign exchange fluctuations, revenues grew 3%. Revenues for the first nine months of 2015 amounted to $14.8 billion, a decrease of 2% compared to the first nine months of 2014. In local currency terms, revenues increased 5% Non-GAAP operating income of $1.6 billion, an increase of 2% compared to the third quarter of 2014. GAAP operating income of $1.0 billion. Non-GAAP net income of $1.2 billion, up 1%. GAAP net income of $103 million. Quarterly non-GAAP EPS of $1.35, an increase... More
